Compare LSBK & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSBK | DERM |
|---|---|---|
| Founded | 1891 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.0M | 135.3M |
| IPO Year | 2025 | 2021 |
| Metric | LSBK | DERM |
|---|---|---|
| Price | $15.69 | $5.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | 8.6K | ★ 322.5K |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | ★ 49.23 | 34.72 |
| EPS | ★ 0.97 | N/A |
| Revenue | N/A | ★ $61,858,000.00 |
| Revenue This Year | N/A | $47.42 |
| Revenue Next Year | N/A | $55.93 |
| P/E Ratio | $16.19 | ★ N/A |
| Revenue Growth | N/A | ★ 10.20 |
| 52 Week Low | $11.50 | $4.31 |
| 52 Week High | $16.22 | $9.56 |
| Indicator | LSBK | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 54.50 | 36.76 |
| Support Level | $15.26 | $4.31 |
| Resistance Level | $15.68 | $8.12 |
| Average True Range (ATR) | 0.17 | 0.31 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 71.43 | 80.45 |
Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.